MethylGene Inc (MYG) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 32 PAGES: 39

More Info
									        MethylGene Inc. (MYG) - Financial and Strategic SWOT Analysis Review
        Reference Code: GDPH61725FSA                                                                                          Publication Date: APR 2013

          7220 Frederick-Banting, Suite 200                  Phone              +1 514 3373333                  Revenue          NA
          Montreal, QC                                       Fax                +1 514 3370550                  Net Profit       -9.73 (million CAD)
          H4S 2A1                                            Website            www.methylgene.com              Employees        NA
                                                                                MYG [Toronto         Stock                       Pharmaceuticals           &
          Canada                                             Exchange                                           Industry
                                                                                Exchange]                                        Healthcare

       Company Overview
       MethylGene Inc. (MethylGene) is a development stage biopharmaceutical company. It discovers, develops and markets novel
       therapeutics for the treatment of cancer and infectious diseases. The company's product pipeline consists of MGCD290 (Hos2
       fungal inhibitor), MGCD265 (Met/VEGF kinase inhibitor), MG516 (Eph/Met kinase inhibitor) and MG96077 (beta-la ctamase
       inhibitor). It develops these products for the treatment of cancer, nuerodegenration, fungal infections, ocular diseases and
       bacterial infections. MethylGene's partnered products include mocetinostat (HDAC inhibitor), EVP-0334 (HDAC inhibitor) and
       Kinase inhibitors.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      MethylGene Inc., SWOT Analysis
         Martin Godbout, Ph.D.               Chairman                                 Strengths                              Weaknesses
         Charles M. Baum, M.D., Chief Executive Officer
                                                                                      Sturdy Research and                    Weak Financial Performance
         Ph.D.
                                                                                      Development
         Henry J. Fuchs, M.D.                Director                                                                        Lack of Commercial Products
                                                                                      Target-Specific Drugs
         Peggy Mulligan                      Director
         Rodney Lappe, Ph.D.                 Director
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                          Threats
        Research, GlobalData
                                                                                      Biotech Focus                          Tightening of the FDA’s
       Share Data                                                                                                            Regulatory Oversight
                                                                                      Collaborative Agreements
         MethylGene Inc.
                                                                                                                             Fierce Competition
        Share Price (CAD) as on 22-Apr-                                  0.11
        2013
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (CAD)                                                       -0.04        GlobalData
        Market Cap (million CAD)                                           33
        Enterprise Value (million CAD)                                     28
        Shares Outstanding (million)                                     318
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Mar 14, 2013         MethylGene Appoints Mark Gergen As CFO
                                                                                      Mar 13, 2013         MethylGene Reports 2012 Results
                                                                                      Feb 19, 2013         MethylGene Appoints Mark Gergen As COO
                                                                                      Nov 14, 2012         MethylGene Reports Q3 2012 Results
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData




       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




MethylGene Inc. (MYG) - Financial and Strategic SWOT Analysis                                                                  Reference Code: GDPH61725FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       MethylGene Inc. - Key Facts .............................................................................................................................................................. 5
       MethylGene Inc. - Key Employees ..................................................................................................................................................... 6
       MethylGene Inc. - Key Employee Biographies ................................................................................................................................... 7
       MethylGene Inc. - Major Products and Services ................................................................................................................................ 8
       MethylGene Inc. - Pharmaceutical Pipeline Products Data ................................................................................................................ 9
          MethylGene Inc., Pipeline Products by Therapy Area .................................................................................................................... 9
          MethylGene Inc., Pipeline Products by Development Phase ........................................................................................................ 10
       MethylGene Inc. - History ................................................................................................................................................................. 12
       MethylGene Inc. - Company Statement ........................................................................................................................................... 15
       MethylGene Inc. - Locations And Subsidiaries ................................................................................................................................. 19
          Head Office ................................................................................................................................................................................... 19
          Other Locations & Subsidiaries ..................................................................................................................................................... 19
       Section 2 – Company Analysis ......................................................................................................................................................... 20
       MethylGene Inc. - Business Description ........................................................................................................................................... 20
       MethylGene Inc. - SWOT Analysis ................................................................................................................................................... 21
          SWOT Analysis - Overview........................................................................................................................................................... 21
          MethylGene Inc. - Strengths ......................................................................................................................................................... 21
             Strength - Sturdy Research and Development .......................................................................................................................... 21
             Strength - Target-Specific Drugs ............................................................................................................................................... 21
             Strength - First in Class Drug Candidate ................................................................................................................................... 21
          MethylGene Inc. - Weaknesses .................................................................................................................................................... 21
             Weakness - Weak Financial Performance ................................................................................................................................ 21
             Weakness - Lack of Commercial Products................................................................................................................................ 22
          MethylGene Inc. - Opportunities ................................................................................................................................................... 22
             Opportunity - Biotech Focus ...................................................................................................................................................... 22
             Opportunity - Collaborative Agreements ................................................................................................................................... 22
             Opportunity - Market Potential: Cancer Therapeutics................................................................................................................ 22
          MethylGene Inc. - Threats ............................................................................................................................................................ 23
             Threat - Tightening of the FDA’s Regulatory Oversight ............................................................................................................. 23
             Threat - Fierce Competition....................................................................................................................................................... 23
             Threat - Uncertain R&D outcomes ............................................................................................................................................ 23
       MethylGene Inc. - Key Competitors.................................................................................................................................................. 24
       Section 3 – Company Financial Ratios ............................................................................................................................................. 25
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 25
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 25
       Performance Chart ........................................................................................................................................................................... 27
       Financial Performance...................................................................................................................................................................... 27
       Financial Ratios - Interim Ratios....................................................................................................................................................... 28
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 29
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 30
          MethylGene Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 .................................................................. 30


MethylGene Inc. (MYG) - Financial and Strategic SWOT Analysis                                                                                                  Reference Code: GDPH61725FSA
Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          MethylGene Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ................................................................. 31
       MethylGene Inc., Recent Deals Summary........................................................................................................................................ 32
       Section 5 – Company’s Recent Developments ................................................................................................................................ 33
          MethylGene Inc., Recent Developments....................................................................................................................................... 33
             Mar 14, 2013: MethylGene Appoints Mark Gergen As CFO ..................................................................................................... 33
             Mar 13, 2013: MethylGene Reports 2012 Results .................................................................................................................... 33
             Feb 19, 2013: MethylGene Appoints Mark Gergen As COO ..................................................................................................... 34
             Nov 14, 2012: MethylGene Reports Q3 2012 Results............................................................................................................... 35
             Nov 12, 2012: MethylGene Appoints Charles Baum As CEO ................................................................................................... 36
             Sep 24, 2012: MethylGene Announces Senior Management Changes .................................................................................... 36
             Aug 02, 2012: MethylGene Reports Q2 2012 Results............................................................................................................... 36
             May 14, 2012: MethylGene Reports Q1 2012 Results .............................................................................................................. 36
             Mar 19, 2012: MethylGene Appoints Peggy Mulligan To Board ................................................................................................ 37
             Mar 15, 2012: MethylGene Reports Q4 2011 Results ............................................................................................................... 37
       Section 6 – Appendix ....................................................................................................................................................................... 38
          Methodology ................................................................................................................................................................................. 38
          Ratio Definitions ............................................................................................................................................................................ 38
          About GlobalData ......................................................................................................................................................................... 42
          Contact Us .................................................................................................................................................................................... 42
          Disclaimer ..................................................................................................................................................................................... 42




MethylGene Inc. (MYG) -
								
To top